NCI Cancer Prevention Fellowship Seeks Passionate Applicants to Drive the Field ForwardMay 25, 2021 | By Susan Jenks
Preventing cancer today and in the future lies at the heart of the National Cancer Institute’s competitive postdoctoral fellowship program, which is accepting candidate applications for the 2022 class until August 16, 2021.
The multidisciplinary Cancer Prevention Fellowship Program (CPFP) selects 10 to 15 new fellows each year and provides up to 4 years of support for mentored research and professional development at the NCI. It additionally offers the opportunity for fellows to earn a master’s degree in public health depending on their previous academic training.
The Search for Early Detection of Pancreatic Cancer Accelerates with BiomarkersApril 27, 2021 | By Susan Jenks
Scientists have identified more than 1,000 potential new biomarkers for cancer that they hope will aid in the early detection of many of these complex diseases, including one of the most challenging, pancreatic cancer.
Pancreatic cancers have long defied early detection with the vast majority diagnosed in advanced stages when they are especially lethal. The 5-year relative survival rate for patients with widespread disease is just 3%. The 5-year survival for all stages in this cancer remains grim, less than 11%. If current trends persist, within a decade these relatively rare...
Pancreatic Cysts Are Monitored in New Trial Aimed at Reducing Cancer Risk Through Targeted ScreeningApril 8, 2021 | By Susan Jenks
In a new NCI-sponsored study now recruiting participants, investigators will evaluate two different screening strategies for non-cancerous pancreatic cysts to determine which works best at detecting early malignancy.
Even though few of these sac-like structures are likely to develop into pancreatic cancer, researchers said, accurately predicting which cysts pose the highest cancer risk is essential to improving prevention and early detection.
“These surveillance strategies have never been tested prospectively before for their clinical benefit or relative costs and benefits...
Cannabis and Cancer Part 2: Scientists Look for Ways to Increase Knowledge About Cannabis with Help from People with CancerMarch 8, 2021 | By NCI Staff
After decades of opposition to decriminalizing cannabis products (especially marijuana), a more permissive attitude toward cannabis and its derivative products has taken hold today at the state level. At the same time, inconsistencies in state policies conflict with federal law, which itself, scientists said at a recent NCI-sponsored Cannabis, Cannabinoids, and Cancer Research Symposium, is hampering clinical research.
Standing on the Shoulders of Giants: Honoring the Scientists who Shaped Cancer Prevention Research During the Last 50 YearsMarch 1, 2021 | By Philip E. Castle, Ph.D., M.P.H.
For centuries, visionary physicians have stressed preventing disease as the best option. I frequently say that the “best” cancer is the cancer that never happens. Today, we turn our attentions to the scientists who made stride after stride during the last 50 years to shape cancer prevention research.
Fifty years ago, the National Cancer Act was signed into law, kick-starting research that has changed how cancer is prevented, detected, diagnosed, treated, and survived, and moving us closer to a time when no one dies of cancer.
Cannabis and Cancer, Part 1: Despite Lack of Evidence, Cannabis Products Being Widely UsedFebruary 24, 2021 | By DCP Staff
During chemotherapy for an advanced blood cancer, Stacey Blansky vaped marijuana daily for her nausea and used cannabis oil for anxiety and stress. The decision to add these complex, plant-derived substances to ease her treatment’s side effects came after doing her own research on possible benefits, she said.
In fact, while many patients say they experience symptom relief with cannabis products, there is no clear evidence on the benefits or potential harms, how cannabis interacts with the different cancer treatment agents, and whether it might modify or reduce the efficacy of...
Second Report Suggests No Benefit to Starting Aspirin Therapy for Cancer Prevention for Adults 70 and OlderFebruary 11, 2021 | By Susan Jenks
Millions of older Americans take aspirin daily to reduce their risk for heart disease and colorectal cancer. But, new data suggests this protective edge for colorectal cancer comes only if they begin taking aspirin before age 70.
In a pooled analysis of two large U.S. cohorts of health professionals, researchers confirmed the surprise finding of an earlier clinical trial, known as ASPREE (Aspirin in Reducing Events in the Elderly). That study found regular aspirin use confers no apparent protection against the development of these cancers in an elderly population.
Study With Common Pain Drug Shows Change in Immune Biomarkers, Highlights Pathway for Prevention of Colorectal Cancer in People with Lynch SyndromeFebruary 3, 2021 | By Susan Jenks
An over-the-counter drug, readily available to consumers for years, may open a new option for preventing colorectal cancer in high-risk individuals.
It's not the mouse that roared but the quiet mouse behind the scenes that inspired researchers to look at the anti-inflammatory drug, naproxen, said Asad Umar, D.V.M., Ph.D., senior advisor to the director for translational research in the National Cancer Institute’s Division of Cancer Prevention and one of the study authors.
Scientific Achievements During 2020: An Unforgettable Year of Progress in the NCI Division of Cancer PreventionDecember 17, 2020 | By Philip E. Castle, Ph.D., M.P.H.
As this unforgettable year of 2020 comes to an end, I am reaching the milestone of my first 6 months as Director of the NCI Division of Cancer Prevention (DCP). It has been a whirlwind of virtual meetings and introductions. I remain humbled and honored by this opportunity to serve and to rejoin DCP with its rich history of leading cancer prevention science in the U.S. and globally.
DCP sponsors and directs groundbreaking, rigorous, collaborative research to revolutionize and accelerate prevention of cancer and its consequences. I am in awe of the breadth and depth of the division’s...
Making Informed Choices on Incorporating Chemoprevention Into Breast Care: Q & A with Dr. Katherine Crew on the MiCHOICE TrialDecember 8, 2020 | By DCP Staff
The SWOG Cancer Research Network is opening to accrual the MiCHOICE Trial to study the use of decision support tools by women with high-risk breast conditions and their healthcare providers to choose among chemoprevention options. The MiCHOICE Trial was previously mentioned in the November 19 Cancer Prevention Science blog post How Patients and Their Doctors Determine Cancer Risk—and What Happens Next.
About 415 high-risk women and 200 healthcare providers will be enrolled through the NCI Community Oncology Research Program (NCORP) to the cluster randomized controlled...